Tumor cells expressing MHC-presented tumor-associated antigens (MHC-TAA tumor cells)

Tumor cells expressing MHC-presented tumor-associated antigens (TAAs) represent a critical target class for modern cancer immunotherapy, particularly for T-cell receptor (TCR) based therapies and bispecific T-cell engagers. These targets are formed when intracellular proteins, including mutated neoantigens or overexpressed self-antigens, are degraded by the proteasome into short peptides and loaded onto Major Histocompatibility Complex (MHC) molecules for surface display (Nature Reviews Cancer, 2021). This presentation allows the immune system to monitor the internal health of the cell, providing a pathway to target oncogenic drivers that do not have traditional surface expression. Drugs like Tebentafusp and Afamitresgene autoleucel are designed to recognize these specific peptide-MHC complexes with high affinity, bypassing the need for natural T-cell recognition (New England Journal of Medicine, 2021; The Lancet, 2024). The therapeutic utility of these targets is highly dependent on the patient's Human Leukocyte Antigen (HLA) haplotype, as the peptide must fit into a specific MHC groove to be recognized by the drug or T-cell (Journal of Clinical Oncology, 2022). While highly effective in inducing targeted cytolysis via the release of perforins and granzymes, this approach faces challenges such as tumor-mediated immune evasion through the downregulation of MHC machinery. Furthermore, safety is a paramount concern, as any cross-reactivity with similar peptides presented on healthy tissues can lead to severe autoimmune-like toxicities (Journal for ImmunoTherapy of Cancer, 2023). Despite these challenges, targeting MHC-presented antigens remains one of the most promising strategies for treating solid tumors that lack unique surface-bound protein markers.

Other names

Peptide-MHC complexpMHCHLA-presented tumor antigensMHC-restricted tumor targetsTumor-specific MHC-peptide complexesAntigen-presenting tumor cells

T-cell receptor (TCR) mediated recognition of specific peptide-MHC complexes leading to cytotoxic T-lymphocyte activation and tumor cell lysis.